On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
- PMID: 23262510
- PMCID: PMC3548588
- DOI: 10.1093/neuonc/nos302
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
Abstract
Background: Glioblastoma multiforme (GBM) is characterized by an aggressive clinical course, therapeutic resistance, and striking molecular heterogeneity. GBM-derived brain tumor stem cells (BTSCs) closely model this molecular heterogeneity and likely have a key role in tumor recurrence and therapeutic resistance. Emerging evidence indicates that Janus kinase (JAK)2/signal transducer and activator of transcription (STAT)3 is an important mediator of tumor cell survival, growth, and invasion in a large group of GBM. Here, we used a large set of molecularly heterogeneous BTSCs to evaluate the translational potential of JAK2/STAT3 therapeutics.
Methods: BTSCs were cultured from GBM patients and MGMT promoter methylation, and the mutation statuses of EGFR, PTEN, and TP53 were determined. Endogenous JAK2/STAT3 activity was assessed in human GBM tissue, BTSCs, and orthotopic xenografts by immunohistochemistry and Western blotting. STAT3 short hairpin (sh)RNA, cucurbitacin-I, and WP1066 were used to inhibit JAK2/STAT3 activity in vitro and in vivo.
Results: The JAK2/STAT3 pathway was demonstrated to be highly activated in human GBM, molecularly heterogeneous BTSCs derived from these tumors, and BTSC xenografts. STAT3 shRNA knockdown or cucurbitacin-I and WP1066 administration resulted in on-target JAK2/STAT3 inhibition and dramatically reduced BTSC survival regardless of endogenous MGMT promoter methylation or EGFR, PTEN, and TP53 mutational status. BTSC orthotopic xenografts maintained the high levels of activated JAK2/STAT3 seen in their parent human tumors. Intraperitoneal WP1066 reduced intratumoral JAK2/STAT3 activity and prolonged animal survival.
Conclusion: Our study demonstrates the in vitro and in vivo efficacy of on-target JAK2/STAT3 inhibition in heterogeneous BTSC lines that closely emulate the genomic and tumorigenic characteristics of human GBM.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3548588/bin/nos30201.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3548588/bin/nos30202.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3548588/bin/nos30203.gif)
![Fig. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3548588/bin/nos30204.gif)
![Fig. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3548588/bin/nos30205.gif)
Similar articles
-
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316808
-
JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.Neuro Oncol. 2014 Sep;16(9):1229-43. doi: 10.1093/neuonc/nou046. Epub 2014 May 25. Neuro Oncol. 2014. PMID: 24861878 Free PMC article.
-
iNOS: a potential therapeutic target for malignant glioma.Curr Mol Med. 2013 Sep;13(8):1241-9. doi: 10.2174/1566524011313080002. Curr Mol Med. 2013. PMID: 23590833 Free PMC article. Review.
-
[Genetic and molecular abnormalities of glioblastomas (GBM)].Bull Cancer. 2010 Nov;97(11):1389-407. doi: 10.1684/bdc.2010.1215. Bull Cancer. 2010. PMID: 21084244 Review. French.
-
Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.J Neurooncol. 2011 Feb;101(3):393-403. doi: 10.1007/s11060-010-0273-y. Epub 2010 Jun 30. J Neurooncol. 2011. PMID: 20589525
Cited by
-
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.Exp Hematol Oncol. 2024 Apr 13;13(1):40. doi: 10.1186/s40164-024-00512-8. Exp Hematol Oncol. 2024. PMID: 38615034 Free PMC article. Review.
-
Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells.Sci Rep. 2023 Dec 9;13(1):21835. doi: 10.1038/s41598-023-48777-z. Sci Rep. 2023. PMID: 38071213 Free PMC article.
-
Tumor-associated astrocytes promote tumor progression of Sonic Hedgehog medulloblastoma by secreting lipocalin-2.Brain Pathol. 2024 Jan;34(1):e13212. doi: 10.1111/bpa.13212. Epub 2023 Sep 18. Brain Pathol. 2024. PMID: 37721122 Free PMC article.
-
Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma.Nat Immunol. 2023 Oct;24(10):1654-1670. doi: 10.1038/s41590-023-01605-y. Epub 2023 Sep 4. Nat Immunol. 2023. PMID: 37667051
-
Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics.Nat Commun. 2023 Aug 19;14(1):5051. doi: 10.1038/s41467-023-40776-y. Nat Commun. 2023. PMID: 37598220 Free PMC article.
References
-
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. - PubMed
-
- Peñuelas S, Anido J, Prieto-Sánchez RM, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15:315–327. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous